Retatrutide, a experimental dual activator of the GLP-1 target and glucose-dependent insulinotropic polypeptide (GIP) receptor , is demonstrating promising data in preliminary clinical trials . Ongoing https://socialskates.com/story22788988/retatrutide-emerging-research-and-projected-clinical-applications